Description

Triple-negative breast cancer (TNBC) is highly resistant to treatment and remains the most challenging subtype of cancer to treat, particularly once it has progressed. There is a need to educate participants regarding the growing understanding of crosstalk between growth factor signaling and ER pathways and the implications of this crosstalk for treating patients with endocrine-resistant tumors.

Learning Objectives

At the end of this educational activity, participants should be able to:
  • Discuss the outcomes of the most recent clinical trials related to the management of women with treatment-resistant breast cancer, including those with triple-negative breast cancer.

Target Audience

This continuing medical education web-based activity is intended for community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.

Faculty

  • Assistant in Medicine, MGH Cancer Center, Massachusetts General Hospital
    Instructor in Medicine, Harvard Medical School

CME Information

Release Date: November 5, 2012
Review: October 18, 2013
Expiration Date: November 4, 2014

On Demand Event Details

To receive credit for the webinar, you must view the presentation and complete the post-test and activity evaluation. Upon completion, you will be able to receive one credit. 

 

Accreditation Information:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Society for Translational Oncology (STO) and Massachusetts General Hospital. The Society for Translational Oncology (STO) is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation: 

STO designates this enduring material for a maximum of one (1) AMA PRA Category 1 Credit TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.


Policy on Faculty and Provider Disclosure
It is the policy of The Society for Translational Oncology (STO) that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. The Society for Translational Oncology (STO) has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.


 

FACULTY DISCLOSURE STATEMENTS

In accord with the disclosure policy of The Society for Translational Oncology (STO) as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.

 

Independent Peer Reviewer Disclosure

 

Reviewer “A” discloses no relevant financial relationships.

 

The following planners of this activity have indicated that neither they nor their spouse/partner have a relevant financial relationship to disclose:

 

Robert J. Birnbaum, MD, PhD

Anan Nathif, EdM

Gabby Cruze

Carol Hardman

The following planner of this activity has indicated that she or her spouse/partner do have a relevant financial relationship to disclose: 

Beverly Moy, MD

Consulting:

GlaxoSmithKline, Pfizer

Updated: 10/3/2012

The following speaker of this activity has indicated that he or his spouse/partner do have a relevant financial relationship to disclose: 

Steven J. Isakoff, MD, PhD

Consulting/Advisory Board:

Myriad Genetics

Research Funding: 

Abbott Pharmaceuticals

Updated: 8/15/2012


Supporters:
This program has received support in the form of educational grants from the following companies:
  • Genentech
  • Genomic Health
  • Novartis

 

 

 


Hardware/Software Specifications: 

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements:
Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh:
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

Supporters

This program has received support in the form of educational grants from the following companies: